Payer decision-making with limited comparative and cost effectiveness data: The case of new pharmacological treatments for gout

Evidence-Based Medicine

Volumn 17, Issue 4, 2012, Pages 105-108

  Meltzer, Michele ^a   Pizzi, Laura T ^b   Jutkowitz, Eric ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jefferson School of Pharmacy   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; PLACEBO;

COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GOUT; HUMAN; LIVER FUNCTION TEST; MEDICAL DECISION MAKING; REVIEW; SIDE EFFECT;

ALLOPURINOL; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION TREES; GOUT; GOUT SUPPRESSANTS; HUMANS; THIAZOLES;

EID: 84865302900     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebmed-2011-100065     Document Type: Review

References (24)

1. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009;151:206-9.
2. Avorn J. Debate about funding comparative-effectiveness research. N Engl J Med 2009;360 :1927-9.
3. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302:1437-43.
4. Chalkidou K, Tunis S, Lopert R, et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 2009;87:339 -67.
5. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending-implications for reform. N Engl J Med 2010;362:460-5.
6. Mikuls TR, Curtis JR, Allison JJ, et al . Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006;33:562-6. (Pubitemid 43334581)
7. Halpern R, Mody RR, Fuldeore MJ, et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009;25:1711 -19.
8. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64:229-58.
9. Vázquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
10. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56. (Pubitemid 14216359)
11. Moreland LW. Febuxostat-treatment for hyperuricemia and gout? N Engl J Med 2005; 353:2505-7.
12. Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009;21:143-9.
13. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48 Suppl 2:ii9-ii14.
14. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30 -8.
15. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med 2010;362: e6.
16. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353 :2450-61. (Pubitemid 41781828)
17. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
18. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94.
19. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering effi cacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
20. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65 :1301-11. (Pubitemid 44641591)
21. National Institute for Health and Clinical Excellence (NICE). NICE technology appraisal guidance 164: febuxostat for the management of hyperuricaemia in people with gout. 2008. http://www.nice.org.uk/nicemedia/pdf/ TA164Guidance.pdf (accessed 11 November 2011).
22. Jansen TL, Richette P, Perez-Ruiz F, et al. International position paper on febuxostat. Clin Rheumatol 2010;29:835-40.
23. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23. (Pubitemid 40372228)
24. Drugstore.com Online Pharmacy. Drug prices for febuxostat and allopurinol. http://www.drugstore.com/.(accessed 11 October 2009).